Beaufort Securities – Speculative Buy rating for Tertiary Minerals

Tertiary Minerals (TYM.L, 1.07p) – Speculative Buy     Tertiary Minerals (TYM) has published more detail about the recently granted Mining Concession at Storuman. Key points include a 25 year life, a licence area of 184 hectares (predominantly limited to the open pit), the permit is solely for the extraction of fluorspar. The announcement also states […]

Advanced Oncotherapy (AVO) – Rocket Science – All Set for Take-off

A research note from Beaufort Securities. A small, young company with limited financial resources, trying to take on giant, established international peers with exceptionally deep pockets, in a product area that both tests the limits of scientific understanding whilst also facing the scrutiny of the world’s most exhaustive regulators? Sounds like a recipe for disaster! […]

Advanced Oncotherapy (AVO) – Recent article and Speculative Buy rating from Beaufort Securities

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, yesterday made two important announcements. One being the realignment of roles and responsibilities of the Executive team, the other being a prospectively far reaching industrialisation agreement with Thales, the giant and highly prestigious French multinational technology design and manufacturing group. 1) The agreement […]

Tertiary Minerals – Speculative Buy

Tertiary Minerals (TYM.L, 1.50p) – Speculative Buy Tertiary Minerals, the AIM-listed company focused on the identification, acquisition, exploration and development of mineral projects in the fluorspar sector, announced last week that its Managing Director, Richard Clemmey, had purchased a further 131,533 ordinary shares at a price of 1.5p. Following the acquisition, Mr Clemmey has a total […]

Advanced Oncotherapy (AVO) – “With every announcement the credibility grows”

Advanced Oncotherapy “with every announcement the credibility grows” Advanced Oncotherapy (AVO) announced yesterday that it has signed a joint venture agreement with CircleHealth to operate the Company’s proton beam cancer therapy centre in Harley Street. CircleHealth, owned by AIM-listed Circle Holdings plc (CIRC) which is an employee co-owned company, runs hospitals and healthcare across the […]

Advanced Oncotherapy – Broker Notes

Advanced Oncotherapy Broker Notes Westhouse retains a Buy recommendation with a Target Price of 25p. Advanced Oncotherapy (AVO) – Analyst Robert Sanders – On Schedule. Two CCL modules are announced as ready for high-power testing. This is the first time two CCL modules will be tested together…the finished proton beam cancer treatment machine (LIGHT system) […]